title: In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
authors.affiliation: Division of Dermatology, Department of Clinical Molecular Medicine Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. hnagai@med.kobe-u.ac.jp
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nagai
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Horikawa
authors.forename: Isao
authors.initials: I
authors.lastname: Hara
authors.forename: Atsushi
authors.initials: A
authors.lastname: Fukunaga
authors.forename: Shuntaro
authors.initials: S
authors.lastname: Oniki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Oka
authors.forename: Chikako
authors.initials: C
authors.lastname: Nishigori
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Ichihashi
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology; D045744:Cell Line, Tumor; D018014:Gene Transfer Techniques; D018664:Interleukin-12 / Q000235:genetics; D007694:Killer Cells, Natural / Q000166:cytology; D008212:Lymphocyte Depletion; D008545:Melanoma / Q000473:pathology / Q000628:therapy*; D051379:Mice; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2; D018664:Interleukin-12